Roughly 20 million people in the US, UK and EU take GLP-1 receptor agonists such as tirzepatide and semaglutide, sold under brands like Ozempic and Mounjaro, for weight loss and type 2 diabetes. As use has surged, side-effects are getting more scrutiny, and hair loss has drawn particular attention f